The Manufacturers Life Insurance Company Trims Stake in Edwards Lifesciences Corporation $EW

Key Points

• The Manufacturers Life Insurance Company reduced its stake in Edwards Lifesciences Corporation by 22.7%, owning approximately 0.17% of the company after selling 291,496 shares.
• Edwards Lifesciences reported a quarterly EPS of $0.67, exceeding expectations, with revenues of $1.53 billion, marking an 11.9% year-over-year increase.
• Brokerages have recently adjusted their price targets for Edwards Lifesciences, with Stifel Nicolaus raising it to $95.00 while maintaining a "buy" rating on the stock.

The Manufacturers Life Insurance Company reduced its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 22.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 993,453 shares of the medical research company's stock after selling 291,496 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.17% of Edwards Lifesciences worth $72,003,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in EW. Vega Investment Solutions bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $27,000. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $26,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $27,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $29,000. Finally, Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $29,000. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

EW has been the subject of a number of research analyst reports. Truist Financial increased their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Stifel Nicolaus raised their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Wall Street Zen upgraded shares of Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Barclays boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Finally, Robert W. Baird boosted their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $85.90.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at $15,565,087. The trade was a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,014 shares of company stock valued at $1,698,844 in the last three months. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Down 0.6%

Shares of NYSE:EW traded down $0.51 during trading on Thursday, hitting $80.71. The stock had a trading volume of 1,331,823 shares, compared to its average volume of 4,462,812. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The company has a market capitalization of $47.39 billion, a PE ratio of 11.62, a PEG ratio of 3.92 and a beta of 1.07. The firm's fifty day moving average is $78.63 and its 200 day moving average is $75.14. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the company earned $0.70 EPS. The business's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.